MIRM Zilurgisertib: Atebrioz Approved for FOP Sept 25

APPROVED September 25, 2026: The FDA approved Atebrioz (zilurgisertib) for FOP in patients 12 and older, one day ahead of the September 26 PDUFA date. This primer was written ahead of the decision and is kept for the PROGRESS data and competitive context. Read the approval article.

Mirum Pharmaceuticals (MIRM) went into its catalyst week with the decision already written off by many investors as a foregone conclusion. On September 25 the FDA approved zilurgisertib, an oral ALK2 inhibitor for fibrodysplasia ossificans progressiva. For a plain-English explainer of what that deadline means, see the PDUFA date guide. Mirum is worth $5.82 billion at $89.70 a share, and it paid Incyte just $16 million upfront for the worldwide rights. The surface story is clean: oral beats injectable, a second entrant follows Regeneron’s Pasatru into a market with zero good options. The real story is messier, and that mess is where the money is. Zilurgisertib’s primary endpoint missed. The FDA accepted the application anyway. This is not a sure thing.

First, the disease. FOP is an ultra-rare genetic disorder in which a mutated ALK2 (ACVR1) receptor drives the body to form bone inside muscle, tendon, and ligament. Roughly 97% of patients carry the same R206H mutation, a single amino acid swap that leaves the receptor stuck in the “on” position and triggers the BMP signaling cascade that builds ectopic bone. The disease affects about one in two million people, an estimated 800 patients in the US. Every new lesion is a step toward locked joints, a fused jaw, a chest wall that can no longer expand to breathe. There is no cure. Until August 2023 there was no drug at all. A market this small, with this much unmet need, is where orphan pricing lives. For how ultra-rare drugs price and what insurers tolerate, see the orphan drug pricing guide.

The data zilurgisertib brings to the table is genuinely strong on volume and genuinely soft on its headline number. The PROGRESS study (NCT05090891) randomized 63 patients aged 12 and older to 100 mg once-daily zilurgisertib (n=32) or placebo (n=31) for 24 weeks, with whole-body CT as the readout. The primary endpoint, the occurrence of any new HO lesion, did not reach statistical significance. One patient on drug developed a new lesion versus five on placebo, an 81% reduction that landed at p=0.0986. That is a miss, plain and simple.

The secondary endpoints are what the FDA is actually looking at. Total new lesion volume fell more than 99% versus placebo, 0.003 cm3 on drug against 6.57 cm3 on placebo, at p<0.0001. Total lesion volume dropped 3.24 cm3 in the treated arm while placebo patients gained 24.64 cm3, p=0.004. And the durability data: among the 61 patients with 48-week scans, nobody on zilurgisertib developed a new lesion after week 24, and total volume kept shrinking, including in patients who crossed over from placebo. Drug was generally well tolerated. For the full trial record, see ClinicalTrials.gov NCT05090891.

Here is the competitive picture, and it is a three-horse race, not two. Regeneron’s Pasatru (garetosmab), a monthly one-hour IV infusion that blocks the Activin A ligand upstream of ALK2, won approval on August 19 for adults. In the Phase 3 OPTIMA trial it cut new lesions 90% to 94% versus placebo at 56 weeks, with p-values of 0.026 and 0.0274, and it hit its primary endpoint. Regeneron priced it at $1.4 million a year for the average patient, a range of $693,000 to $2.1 million by weight. The Pasatru approval piece called the September 26 zilurgisertib decision the next thing to watch.

Then there is the drug everyone forgets. Ipsen’s Sohonos (palovarotene), a daily oral retinoid, has been approved since August 2023 at $624,000 a year. So the “oral versus injectable” framing is wrong. Zilurgisertib is not the first oral FOP drug; it is the second. The real case for it is the mechanism. Palovarotene works through retinoid signaling with a side-effect profile that has always made clinicians nervous, while zilurgisertib hits the mutated ALK2 receptor directly and selectively. In a disease defined by a single driver mutation, a targeted pill is the cleaner bet than a broad retinoid. That is the argument, and it is a real one.

The valuation is where the stock price stops making obvious sense. Mirum is not a one-asset lottery ticket. It already has LIVMARLI (maralixibat) throwing off real revenue, $176.2 million in Q2 2026, up 37.9% year over year, with full-year guidance raised to $660 to $680 million. That puts the stock at roughly 8.7 times forward sales, which is not cheap but is defensible for a growing rare disease franchise with three other late-stage shots. Zilurgisertib is an option layered on top, and the option is cheap. Mirum paid $16 million upfront for it, with Incyte due development and regulatory milestones plus mid-to-high single-digit royalties on sales. Incyte, worth $25.9 billion, keeps the royalties but carries none of the launch risk. Mirum carries the catalyst.

So what does approval actually add? FOP is 800 US patients. At Sohonos-level pricing of $624,000 a year, a full sweep of the market is a $500 million peak opportunity, and zilurgisertib will not get a full sweep. It will split the field with Pasatru and Sohonos. Call it $150 to $300 million in peak sales for Mirum, most of it years away after the pediatric cohorts read out. Against a $660 million revenue base growing 38%, that is incremental, not transformative. The stock at $89.70 is not pricing in a home run on this drug. It is pricing in a modest, mostly successful outcome — and the decision ultimately broke Mirum’s way on September 25.

The risks are specific, not generic. The approval itself was the live one, and it resolved in Mirum’s favor on September 25. A missed primary endpoint on a Priority Review filing is exactly the kind of thing that can flip to a Complete Response Letter or an AdCom that delays the decision. The volume data is excellent, and the FDA accepted the application, but “accepted” and “approved” are different words. Launch execution adds a second front: Regeneron has a first-mover month, a clean efficacy story, and a home-infusion option that blunts the convenience argument. Further out, Mirum’s real value sits in LIVMARLI and the PSC/PBC pipeline, not in FOP. If those stumble, this catalyst will not save the stock. The biliary atresia program is a separate, earlier-stage risk-reward, and it is the one that moves the valuation needle more over two years.

The broader pattern here is worth naming. In ultra-rare disease, the market consistently overpays for the narrative of “first” and underpays for the harder question of whether a second or third entrant can actually take share in a patient pool measured in the hundreds. Pasatru won the first-mover narrative. Sohonos won it before that. Zilurgisertib is fighting for third in a market where the winner-take-all logic of big oncology does not apply, but where a genuinely better mechanism still matters. That tension, between mechanism quality and crowdedness, is the entire FOP story in one sentence.

The verdict, updated after the decision: The approval came through on September 25, one day early, with a 12-and-up label, vindicating the pre-decision read that the FDA would weigh the near-total reduction in new lesion volume over the missed primary endpoint. The stock closed at $89.70 on September 25. The “hold into the decision” framing is now moot — the binary resolved in Mirum’s favor, and launch execution is the story from here. Mirum now holds the second approved ALK2-directed option in FOP behind Regeneron’s Pasatru, with the LIVMARLI franchise still the valuation anchor and zilurgisertib a realized, if incremental, launch asset rather than a binary option. The oral-ALK2 thesis was sound; the entry price at $96 was the problem, and the decision-and-reaction trade is now the only one left.